{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:15:38Z","timestamp":1789773338647,"version":"4.0.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We developed a new predictive staging system to explore the heterogeneity of survival in newly diagnosed multiple myeloma (NDMM) patients in the real world.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, we evaluated the predictive value of cytogenetic abnormal and clinical data in 375 patients with NDMM at our center. Established a weighted MM prognostic scoring system risk model and validated its predicted PFS and OS by external cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Elevated lactate dehydrogenase levels (1 point), international staging system stage II\/III (1 point), 1q21+ \u2265 52.75% (0.5 point), del (17p) \u2265 3.5% (0.5 point), and t (14;16) \u2265 35.25% (1 point) had independent prognostic significance. Patients were further divided into three risk groups: low (I) (score 0\u20130.5, 16.5%), intermediate (II) (score 1, 46.7%), and high (III) (score 1.5\u20133, 36.8%). In the training cohort, the 3-year PFS was 79.5% vs. 65.3% vs. 40.3% (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), and the 3-year OS was 87.7% vs.70.1% vs. 55% (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) for the three risk groups. In the external validation cohort, the 3-year PFS was 85.5% vs.61.2% vs. 43.1% (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) and the 3-year OS was 91.4% vs.83.5% vs. 56.9% (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) for the three risk groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The risk stratification of this model shows good discrimination and calibration, and its application in clinical practice can improve the risk assessment of patients with NDMM and guide personalized treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1473034","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T12:16:37Z","timestamp":1729599397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs"],"prefix":"10.3389","volume":"11","author":[{"given":"Ye","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y2","article-title":"The multiple myelomas \u2013 current concepts in cytogenetic classification and therapy.","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma.","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group.","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/jco.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project.","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma.","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27207","article-title":"Development and validation of an individualized and weighted myeloma prognostic score system (MPSS) in patients with newly diagnosed multiple myeloma.","volume":"1","author":"Mao","year":"2024","journal-title":"Am J Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.26774","article-title":"Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.","volume":"98","author":"Yang","year":"2023","journal-title":"Am J Hematol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2177979","article-title":"Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: Results from a single-center study.","volume":"28","author":"Chen","year":"2023","journal-title":"Hematology."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24375","article-title":"Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.","volume":"36","author":"Wang","year":"2022","journal-title":"J Clin Lab Anal."},{"key":"B11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clml.2022.01.013","article-title":"The importance of FISH signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: Is it underestimated?","volume":"22","author":"Gao","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00807-9","article-title":"Multiple myeloma with t(11;14): Impact of novel agents on outcome.","volume":"13","author":"Puertas","year":"2023","journal-title":"Blood Cancer J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach.","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders.","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/jco.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.","volume":"30","author":"Avet-Loiseau","year":"2012","journal-title":"J Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0255-z","article-title":"Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.","volume":"9","author":"Smadbeck","year":"2019","journal-title":"Blood Cancer J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: A framework for traditional and novel measures.","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and interpreting decision curve analysis: A guide for investigators.","volume":"74","author":"Van Calster","year":"2018","journal-title":"Eur Urol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41409-020-0829-1","article-title":"LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation.","volume":"55","author":"Shouval","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/bs9.0000000000000077","article-title":"Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma.","volume":"3","author":"Luo","year":"2021","journal-title":"Blood Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/jco.2013.53.0329","article-title":"Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and\/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.","volume":"32","author":"Moreau","year":"2014","journal-title":"J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.Ccr-14-2576","article-title":"The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.","volume":"21","author":"An","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00933-4","article-title":"Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.","volume":"13","author":"Schavgoulidze","year":"2023","journal-title":"Blood Cancer J."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00978-z","article-title":"Translocation t(14;16) in multiple myeloma: Gangster or just part of the gang?","volume":"14","author":"Mian","year":"2024","journal-title":"Blood Cancer J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.25758","article-title":"A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.","volume":"95","author":"Goldman-Mazur","year":"2020","journal-title":"Am J Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajh.27419","article-title":"Still high risk? A review of translocation t(14;16) in multiple myeloma.","author":"Mian","year":"2024","journal-title":"Am J Hematol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938550","article-title":"Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.1002\/cam4.3254","article-title":"Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.","volume":"9","author":"Gao","year":"2020","journal-title":"Cancer Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00277-016-2692-0","article-title":"Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and\/or t(4;14) and overcomes their adverse prognosis.","volume":"95","author":"El-Ghammaz","year":"2016","journal-title":"Ann Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/jco.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2161222","article-title":"Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.","volume":"28","author":"Geng","year":"2023","journal-title":"Hematology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1473034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T12:16:39Z","timestamp":1729599399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1473034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":32,"alternative-id":["10.3389\/fmed.2024.1473034"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1473034","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"article-number":"1473034"}}